Infection, Antimicrobials, Modelling, Evolution Research Center, Université de Paris (Paris-Diderot), UMR 1137, Paris, France.
Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat, Paris, France.
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure (70.8% [17/24]), microbiological eradication (58.3% [14/24]), and day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% [4/10], 30.0% [3/10], and 50.0% [5/10], respectively).
在 CREDIBLE-CR 和 APEKS-NP 研究中，头孢地尔治疗产金属β-内酰胺酶的革兰氏阴性菌有效；临床治愈率（70.8%[17/24]）、微生物清除率（58.3%[14/24]）和 28 天全因死亡率（12.5%[3/24]）与最佳可用治疗药物和高剂量美罗培南的对照药物相比具有优势（分别为 40.0%[4/10]、30.0%[3/10]和 50.0%[5/10]）。
